In this study, we aim to characterize PD-L1 expression in EGFR-mutant NSCLC patients and examine the association between EGFR mutation subtypes and clinical parameters, including age, sex, histologic subtype, first-line treatment, overall survival, and progression-free survival. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.